362 related articles for article (PubMed ID: 32909841)
1. Emerging therapies in Friedreich's Ataxia.
Zesiewicz TA; Hancock J; Ghanekar SD; Kuo SH; Dohse CA; Vega J
Expert Rev Neurother; 2020 Dec; 20(12):1215-1228. PubMed ID: 32909841
[TBL] [Abstract][Full Text] [Related]
2. Targeting lipid peroxidation and mitochondrial imbalance in Friedreich's ataxia.
Abeti R; Uzun E; Renganathan I; Honda T; Pook MA; Giunti P
Pharmacol Res; 2015 Sep; 99():344-50. PubMed ID: 26141703
[TBL] [Abstract][Full Text] [Related]
3. Targeting NRF2 for the Treatment of Friedreich's Ataxia: A Comparison among Drugs.
Petrillo S; D'Amico J; La Rosa P; Bertini ES; Piemonte F
Int J Mol Sci; 2019 Oct; 20(20):. PubMed ID: 31640150
[TBL] [Abstract][Full Text] [Related]
4. Interferon Gamma Enhances Cytoprotective Pathways via Nrf2 and MnSOD Induction in Friedreich's Ataxia Cells.
Luffarelli R; Panarello L; Quatrana A; Tiano F; Fortuni S; Rufini A; Malisan F; Testi R; Condò I
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37628866
[TBL] [Abstract][Full Text] [Related]
5. Friedreich's Ataxia: from the (GAA)n repeat mediated silencing to new promising molecules for therapy.
Marmolino D; Acquaviva F
Cerebellum; 2009 Sep; 8(3):245-59. PubMed ID: 19165552
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapeutic strategies for Friedreich Ataxia: a review of the available data.
Gunther K; Lynch DR
Expert Opin Pharmacother; 2024 Apr; 25(5):529-539. PubMed ID: 38622054
[TBL] [Abstract][Full Text] [Related]
7. Molecular insights into Friedreich's ataxia and antioxidant-based therapies.
Rötig A; Sidi D; Munnich A; Rustin P
Trends Mol Med; 2002 May; 8(5):221-4. PubMed ID: 12067631
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic approaches for the treatment of Friedreich's ataxia.
Strawser CJ; Schadt KA; Lynch DR
Expert Rev Neurother; 2014 Aug; 14(8):949-57. PubMed ID: 25034024
[TBL] [Abstract][Full Text] [Related]
9. New developments in pharmacotherapy for Friedreich ataxia.
Clay A; Hearle P; Schadt K; Lynch DR
Expert Opin Pharmacother; 2019 Oct; 20(15):1855-1867. PubMed ID: 31311349
[No Abstract] [Full Text] [Related]
10. Omaveloxolone: an activator of Nrf2 for the treatment of Friedreich ataxia.
Profeta V; McIntyre K; Wells M; Park C; Lynch DR
Expert Opin Investig Drugs; 2023 Jan; 32(1):5-16. PubMed ID: 36708320
[TBL] [Abstract][Full Text] [Related]
11. Friedreich's Ataxia: disease mechanisms, antioxidant and Coenzyme Q10 therapy.
Cooper JM; Schapira AH
Biofactors; 2003; 18(1-4):163-71. PubMed ID: 14695932
[TBL] [Abstract][Full Text] [Related]
12. Mitochondrial dysfunction in Friedreich's ataxia: from pathogenesis to treatment perspectives.
Lodi R; Rajagopalan B; Bradley JL; Taylor DJ; Crilley JG; Hart PE; Blamire AM; Manners D; Styles P; Schapira AH; Cooper JM
Free Radic Res; 2002 Apr; 36(4):461-6. PubMed ID: 12069111
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Prospects for Friedreich's Ataxia.
Zhang S; Napierala M; Napierala JS
Trends Pharmacol Sci; 2019 Apr; 40(4):229-233. PubMed ID: 30905359
[TBL] [Abstract][Full Text] [Related]
14. Frataxin deficiency leads to defects in expression of antioxidants and Nrf2 expression in dorsal root ganglia of the Friedreich's ataxia YG8R mouse model.
Shan Y; Schoenfeld RA; Hayashi G; Napoli E; Akiyama T; Iodi Carstens M; Carstens EE; Pook MA; Cortopassi GA
Antioxid Redox Signal; 2013 Nov; 19(13):1481-93. PubMed ID: 23350650
[TBL] [Abstract][Full Text] [Related]
15. PPAR-gamma agonist Azelaoyl PAF increases frataxin protein and mRNA expression: new implications for the Friedreich's ataxia therapy.
Marmolino D; Acquaviva F; Pinelli M; Monticelli A; Castaldo I; Filla A; Cocozza S
Cerebellum; 2009 Jun; 8(2):98-103. PubMed ID: 19104905
[TBL] [Abstract][Full Text] [Related]
16. Frataxin and the molecular mechanism of mitochondrial iron-loading in Friedreich's ataxia.
Chiang S; Kovacevic Z; Sahni S; Lane DJ; Merlot AM; Kalinowski DS; Huang ML; Richardson DR
Clin Sci (Lond); 2016 Jun; 130(11):853-70. PubMed ID: 27129098
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation study.
Libri V; Yandim C; Athanasopoulos S; Loyse N; Natisvili T; Law PP; Chan PK; Mohammad T; Mauri M; Tam KT; Leiper J; Piper S; Ramesh A; Parkinson MH; Huson L; Giunti P; Festenstein R
Lancet; 2014 Aug; 384(9942):504-13. PubMed ID: 24794816
[TBL] [Abstract][Full Text] [Related]
18. Drug repositioning screening identifies etravirine as a potential therapeutic for friedreich's ataxia.
Alfedi G; Luffarelli R; Condò I; Pedini G; Mannucci L; Massaro DS; Benini M; Toschi N; Alaimo G; Panarello L; Pacini L; Fortuni S; Serio D; Malisan F; Testi R; Rufini A
Mov Disord; 2019 Mar; 34(3):323-334. PubMed ID: 30624801
[TBL] [Abstract][Full Text] [Related]
19. Deferiprone and idebenone rescue frataxin depletion phenotypes in a Drosophila model of Friedreich's ataxia.
Soriano S; Llorens JV; Blanco-Sobero L; Gutiérrez L; Calap-Quintana P; Morales MP; Moltó MD; Martínez-Sebastián MJ
Gene; 2013 Jun; 521(2):274-81. PubMed ID: 23542074
[TBL] [Abstract][Full Text] [Related]
20. Fixing frataxin: 'ironing out' the metabolic defect in Friedreich's ataxia.
Anzovino A; Lane DJ; Huang ML; Richardson DR
Br J Pharmacol; 2014 Apr; 171(8):2174-90. PubMed ID: 24138602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
